Important Information for Customers Impacted by Hurricane Sandy
October 29, 2012
We are dedicated to providing services to our customers when they are faced with unusual circumstances. In the event you or your family is impacted by the tropical storms please remember to take the following items with you:
If you or your family needs emergency insulin pump supplies, please contact our Toll Free Medtronic Storm Hotline at 1-800-646-4633 ext. 64545.
Study of Next Step Toward Artificial Pancreas From Medtronic Meets Efficacy Endpoints
February 29, 2012
MINNEAPOLIS - February 29, 2012 - In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that the results of the in-clinic ASPIRE (Automation to Simulate Pancreatic Insulin REsponse) study have been published online and in the March edition of Diabetes Technology & Therapeutics. The ASPIRE study met its efficacy endpoints and showed a 19% reduction in time spent below the low glucose threshold in patients using the MiniMed Paradigm System featuring Low Glucose Suspend (LGS) automation, compared to conventional pump therapy. The LGS feature of the integrated insulin pump and continuous glucose monitor works by automatically suspending insulin delivery if the sensor glucose value is equal to or below the low threshold value. The Paradigm System is commercially available outside the United States but limited to investigational use in the U.S.
Medtronic Launches First-Of-Its-Kind mySentry™ Remote Glucose Monitor
January 4, 2012
MINNEAPOLIS - January 4, 2012 - Today, Medtronic, Inc. (NYSE:MDT) announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind mySentry™ Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient's MiniMed Paradigm® REAL-Time Revel™ System. The remote glucose monitor also marks the launch of a new category of Connected Care solutions that will provide people with diabetes and their caregivers convenient options to access their diabetes management information.
Medtronic Receives FDA Approval for Next Generation Professional Continuous Glucose Monitoring
November 22, 2011
MINNEAPOLIS - November 22, 2011 - Medtronic, Inc. (NYSE:MDT) today announced the Food and Drug Administration (FDA) approval of iPro® 2, a next generation Professional continuous glucose monitoring (CGM) system and the latest in a series of recent diabetes technology approvals and innovations from the company. iPro2 simplifies Professional CGM and enables healthcare providers to obtain a more complete picture of glucose control for the patients they treat. Professional CGM is used by healthcare providers to reveal low (hypoglycemia) and high (hyperglycemia) glucose excursions that can lead to the dangerous health complications of diabetes. These excursions often go unnoticed with traditional A1C tests and standard glucose meter measurements.
Medtronic Begins Enrolling U.S. IDE Study of Enlite™ Sensor for Continuous Glucose Monitoring
November 9, 2011
MINNEAPOLIS - Nov. 9, 2011 - Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in adults with diabetes of its Enlite™ Sensor, the company's latest innovation in continuous glucose monitoring (CGM) technology for people with diabetes. The study will evaluate Enlite, a glucose sensor for CGM designed to offer improved hypoglycemic detection and comfort compared to current CGM sensors. CGM provides a more complete picture of glucose control because it can reveal high and low glucose levels that periodic fingerstick testing might miss.
For media inquiries pertaining to the Diabetes business of Medtronic, please contact:
Director of Public Relations
For all other media inquiries please select the appropriate Global Public and Media Relations contact